A Phase 1 interventional study of Aripiprazole IM Depot in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2014-07-31.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.
Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 100th largest by enrollment of the 125 interventional ones that give a count, is one of 4 that started in 2012, is one of 13 in phase 1, and was the 73rd registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Ages 18–65
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Ages 15–40
By country, each count listing its studies:
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 10 · Phase 3 38 · Phase 4 56
First in 1998; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 130 across the 125 interventional studies. Of the 105 that completed or were terminated, 47 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 90th largest by enrollment of the 111 interventional ones that give a count, is one of 5 that started in 2012, is one of 34 in phase 1, and was the 47th registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
1 of the studies testing aripiprazole in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07547384CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia. | 2027-09-05 |
Add it to your calendar (.ics) → With an account.
Among the 126 studies testing aripiprazole in Schizophrenia, from their registry updates:
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether aripiprazole injection into the shoulder or the buttocks produces similar effects in the body
Extended-release gluteal intramuscular (IM) injection of aripiprazole has been tested in subjects with schizophrenia for safety and tolerability. This study will compare the gluteal IM aripiprazole injection with deltoid IM aripiprazole injection for safety and tolerability.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Deltoid injection site
Drug: Aripiprazole IM Depot
Gluteal injection site
Drug: Aripiprazole IM Depot
One injection of 400 mg aripiprazole IM depot
Also known as: Abilify
Maximum Observed Plasma Concentration (Cmax) of Aripriprazole
Relative bioavailability (Frel) of aripiprazole intramuscular (IM) depot injected in the deltoid muscle compared to the gluteal muscle based on aripiprazole maximum (peak) plasma concentrations (Cmax) PK parameter.
Time frame: Day 1: 4 hr, 8 hr, and 12 hr post dose, Days 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25, 28, 35, 42, 49, 56, 63, 70, 77, 84, 98, 112 and 126/Early termination
Area Under the Concentration-Time Curve Infinity (AUC Infinity); Area Under the Concentration-Time Curve 28 (AUC 28), and Area Under the Concentration-Time Curve t (AUC t): Aripiprazole
Relative bioavailability (Frel) of aripiprazole IM depot injected in the deltoid muscle compared to the gluteal muscle based on area under the concentration-time curve (AUC) from time zero to the time of last measurable concentration (AUCt), AUC time curve 28, and AUC from time zero to infinity PK parameters.
Time frame: Day 1: 4 hr, 8 hr, and 12 hr post dose, Days 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25, 28, 35, 42, 49, 56, 63, 70, 77, 84, 98, 112 and 126/Early termination
Maximum Observed Plasma Concentration (Cmax) of Dehydro-Aripiprazole
Relative bioavailability (Frel) of aripiprazole intramuscular (IM) depot injected in the deltoid muscle compared to the gluteal muscle based on aripiprazole maximum (peak) plasma concentrations (Cmax) PK parameter.
Time frame: Day 1: 4 hr, 8 hr, and 12 hr post dose, Days 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25, 28, 35, 42, 49, 56, 63, 70, 77, 84, 98, 112 and 126/Early termination
Area Under the Concentration-Time Curve Infinity (AUC Infinity); Area Under the Concentration-Time Curve 28 (AUC 28), and Area Under the Concentration-Time Curve t (AUC t): Dehydro-Aripiprazole
Relative bioavailability (Frel) of aripiprazole IM depot injected in the deltoid muscle compared to the gluteal muscle based on area under the concentration-time curve (AUC) from time zero to the time of last measurable concentration (AUCt), AUC time curve 28 and AUC from time zero to infinity PK parameters.
Time frame: Day 1: 4 hr, 8 hr, and 12 hr post dose, Days 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 25, 28, 35, 42, 49, 56, 63, 70, 77, 84, 98, 112 and 126/Early termination
Number of Participants Reporting Treatment Emergent Adverse Events (TEAE).
Safety was measured according to standard adverse event collection as described in the adverse event section of the results.
Time frame: Starting at the time the ICF was signed to Day 126/Early termination
Number of Participants With Laboratory Values of Potential Clinical Relevance.
The laboratory tests were collected and processed in accordance with directions from the clinical chemistry laboratory. Based on criteria for identifying laboratory values of potential clinical relevance, the abnormal values were noted. Some of the criteria are as follows: For fasting triglycerides: men: ≥ 160 mg/dL and women: ≥ 120 mg/dL; Fasting glucose: ≥ 115 mg/dL; Prolactin: \> upper limit of normal (ULN); Neutrophils: ≤ 1,500/mm3; and Creatine phosphokinase: ≥ 3 x ULN.
Time frame: Day 1, Day 28, Day 126/Early termination
Number of Participants With Vital Signs of Potential Clinical Relevance-Blood Pressure
Vital sign assessment included orthostatic (supine and standing) blood pressure. Orthostatic assessments were made after participants had been in the supine position for at least 5 minutes and again after participants had been standing for 2 minutes, but not more than 3 minutes. Orthostatic hypotension defined as \>/= 20 mm Hg decrease in systolic blood pressure and \>/= 25 beats per minute increase in heart rate from supine to standing.
Time frame: Day 1, Day 14, Day 28 and Day 126/Early termination
Number of Participants With Vital Signs of Potential Clinical Relevance-Temperature
Vital sign assessment included body temperature measured in centigrade(C). Temperatures \>=37.8°C and increase of \>= 1.1°C were recorded.
Time frame: Day 1, Day 14, Day 28 and Day 126/Early termination
Number of Participants With Vital Signs of Potential Clinical Relevance-Heart Rate
Vital sign assessment included heart rate (supine and standing). Heart rate with increase or decrease of \>/= 15 beats per minute were recorded.
Time frame: Day 1, Day 14, Day 28 and Day 126/Early termination
Number of Participants With Electrocardiogram (ECG) Measurements of Potential Clinical Relevance
Three 12 lead ECGs were performed approximately 5 minutes apart at each time point. The participant were supine and at rest (for at least 10 minutes) prior to the first ECG and will remain supine through the final ECG. Based on criteria for identifying ECG measurements of potential clinical relevance, the abnormal values were noted. Some of the criteria are as follows: For bradycardia: ≤ 50 beats per minute (bpm); and for increase in QTc: QTc ≥ 450msec.
Time frame: Day 1, Day 14, Day 28 and Day 126/Early termination
Visual Analog Scale (VAS) Score at Day 1, Day 14, Day 28 and Last Visit.
Injection site pain was assessed using a VAS, which was completed by the trial participant, and the investigator's assessment of most recent injection site, which was completed by the investigator. VAS is 100 mm line, 0=no pain, 100=unbearably painful.
Time frame: Day 1, Day 14, Day 28 and last visit
Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale.
This scale consists of a baseline evaluation that assesses the lifetime experience of the participant with suicide events and suicidal ideation and a post baseline evaluation that focuses on suicidality since the last trial visit.
Time frame: Screening, Baseline, Week 1, Week 2, Week 8, Week 18 visit and Last visit.
This report presents results of a study on 37 adults with schizophrenia, conducted at 6 centers in the United States.
| Milestone | Aripiprazole IM Depot 400 mg: Deltoid | Aripiprazole IM Depot 400 mg: Gluteal |
|---|---|---|
| Started | 18 | 19 |
| Completed | 16 | 14 |
| Not completed | 2 | 5 |
| Withdrew: Lost to follow-up | 0 | 3 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Relative bioavailability (Frel) of aripiprazole intramuscular (IM) depot injected in the deltoid muscle compared to the gluteal muscle based on aripiprazole maximum (peak) plasma concentrations (Cmax) PK parameter.
| ng/mL | Aripiprazole IM Depot 400 mg: Deltoid | Aripiprazole IM Depot 400 mg: Gluteal |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Aripriprazole | 170 ± 58.6 | 136 ± 70.3 |
Relative bioavailability (Frel) of aripiprazole IM depot injected in the deltoid muscle compared to the gluteal muscle based on area under the concentration-time curve (AUC) from time zero to the time of last measurable concentration (AUCt), AUC time curve 28, and AUC from time zero to infinity PK parameters.
| ng day/mL | Aripiprazole IM Depot 400 mg: Deltoid | Aripiprazole IM Depot 400 mg: Gluteal |
|---|---|---|
| AUC infinity (n=16,14) | 7590 ± 2590 | 7920 ± 2580 |
| AUC 28 (n=16,17) | 3120 ± 1150 | 2380 ± 1410 |
| AUC t (n=16,17) | 7360 ± 2420 | 7340 ± 2360 |
Relative bioavailability (Frel) of aripiprazole intramuscular (IM) depot injected in the deltoid muscle compared to the gluteal muscle based on aripiprazole maximum (peak) plasma concentrations (Cmax) PK parameter.
| ng/mL | Aripiprazole IM Depot 400 mg: Deltoid | Aripiprazole IM Depot 400 mg: Gluteal |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Dehydro-Aripiprazole | 51.7 ± 23.3 | 34.6 ± 13.2 |
Relative bioavailability (Frel) of aripiprazole IM depot injected in the deltoid muscle compared to the gluteal muscle based on area under the concentration-time curve (AUC) from time zero to the time of last measurable concentration (AUCt), AUC time curve 28 and AUC from time zero to infinity PK parameters.
| ng day/mL | Aripiprazole IM Depot 400 mg: Deltoid | Aripiprazole IM Depot 400 mg: Gluteal |
|---|---|---|
| AUC infinity (n=16,14) | 2520 ± 836 | 2230 ± 630 |
| AUC 28 (n=16,17) | 886 ± 445 | 538 ± 305 |
| AUC t (n=16,17) | 2420 ± 805 | 1990 ± 603 |
Safety was measured according to standard adverse event collection as described in the adverse event section of the results.
| Participants | Aripiprazole IM Depot 400 mg: Deltoid | Aripiprazole IM Depot 400 mg: Gluteal |
|---|---|---|
| Subjects with TEAEs | 14 | 18 |
| Subjects with serious TEAEs | 0 | 0 |
| Subjects with severe TEAEs | 1 | 1 |
The laboratory tests were collected and processed in accordance with directions from the clinical chemistry laboratory. Based on criteria for identifying laboratory values of potential clinical relevance, the abnormal values were noted. Some of the criteria are as follows: For fasting triglycerides: men: ≥ 160 mg/dL and women: ≥ 120 mg/dL; Fasting glucose: ≥ 115 mg/dL; Prolactin: \> upper limit of normal (ULN); Neutrophils: ≤ 1,500/mm3; and Creatine phosphokinase: ≥ 3 x ULN.
| Participants | Aripiprazole IM Depot 400 mg: Deltoid | Aripiprazole IM Depot 400 mg: Gluteal |
|---|---|---|
| High fasting triglycerides (n=9,11) | 3 | 5 |
| High fasting glucose (n=9,11) | 3 | 0 |
| High prolactin (n=17,18) | 3 | 3 |
| Low absolute neutrophils (n=17,18) | 1 | 2 |
| High creatine phosphokinase (n=17,18) | 2 | 0 |
Vital sign assessment included orthostatic (supine and standing) blood pressure. Orthostatic assessments were made after participants had been in the supine position for at least 5 minutes and again after participants had been standing for 2 minutes, but not more than 3 minutes. Orthostatic hypotension defined as \>/= 20 mm Hg decrease in systolic blood pressure and \>/= 25 beats per minute increase in heart rate from supine to standing.
| Participants | Aripiprazole IM Depot 400 mg: Deltoid | Aripiprazole IM Depot 400 mg: Gluteal |
|---|---|---|
| Increase >/=15 mmHg in diastolic standing BP | 0 | 1 |
| Orthostatic hypotension | 0 | 0 |
Vital sign assessment included body temperature measured in centigrade(C). Temperatures \>=37.8°C and increase of \>= 1.1°C were recorded.
| Participants | Aripiprazole IM Depot 400 mg: Deltoid | Aripiprazole IM Depot 400 mg: Gluteal |
|---|---|---|
| Number of Participants With Vital Signs of Potential Clinical Relevance-Temperature | 0 | 0 |
Vital sign assessment included heart rate (supine and standing). Heart rate with increase or decrease of \>/= 15 beats per minute were recorded.
| Participants | Aripiprazole IM Depot 400 mg: Deltoid | Aripiprazole IM Depot 400 mg: Gluteal |
|---|---|---|
| Heart rate: Supine: increase | 0 | 0 |
| Heart rate: Supine: decrease | 0 | 0 |
| Heart rate: Standing: increase | 0 | 0 |
| Heart rate: Standing: decrease | 0 | 0 |
Three 12 lead ECGs were performed approximately 5 minutes apart at each time point. The participant were supine and at rest (for at least 10 minutes) prior to the first ECG and will remain supine through the final ECG. Based on criteria for identifying ECG measurements of potential clinical relevance, the abnormal values were noted. Some of the criteria are as follows: For bradycardia: ≤ 50 beats per minute (bpm); and for increase in QTc: QTc ≥ 450msec.
| Participants | Aripiprazole IM Depot 400 mg: Deltoid | Aripiprazole IM Depot 400 mg: Gluteal |
|---|---|---|
| premature ventricular contractions | 2 | 1 |
| T-wave inversions | 2 | 2 |
| Bradycardia and sinus bradycardia | 0 | 1 |
| Abnormalities in QTc intervals | 0 | 0 |
Injection site pain was assessed using a VAS, which was completed by the trial participant, and the investigator's assessment of most recent injection site, which was completed by the investigator. VAS is 100 mm line, 0=no pain, 100=unbearably painful.
| Units on a scale | Aripiprazole IM Depot 400 mg: Deltoid | Aripiprazole IM Depot 400 mg: Gluteal |
|---|---|---|
| Day 1: 0.5 hour pre-dose (n=17, 18) | 1.2 ± 3.4 | 0.8 ± 1.6 |
| Day 1: 1 hour post-dose (n=17, 18) | 3.1 ± 7.3 | 1.7 ± 2.7 |
| Day 14 (n=16, 18) | 1.3 ± 3.7 | 0.3 ± 0.8 |
| Day 28 (n=16, 18) | 0.5 ± 1.1 | 0.5 ± 1.3 |
| Last visit (n=17, 18) | 2.2 ± 7.2 | 0.5 ± 1.3 |
This scale consists of a baseline evaluation that assesses the lifetime experience of the participant with suicide events and suicidal ideation and a post baseline evaluation that focuses on suicidality since the last trial visit.
| Participants | Aripiprazole IM Depot 400 mg: Deltoid | Aripiprazole IM Depot 400 mg: Gluteal |
|---|---|---|
| Screening: Suicidality (n=17,18) | 4 | 7 |
| Screening: Suicidal behaviour (n=17,18) | 2 | 5 |
| Screening: Suicidal ideation (n=17,18) | 4 | 7 |
| Baseline: Suicidality (n=17,18) | 0 | 0 |
| Baseline: Suicidal behaviour (n=17,18) | 0 | 0 |
| Baseline: Suicidal ideation (n=17,18) | 0 | 0 |
| Week 1: Suicidality (n=17,18) | 0 | 0 |
| Week 1: Suicidal behaviour (n=17,18) | 0 | 0 |
| Week 1: Suicidal ideation (n=17,18) | 0 | 0 |
| Week 2: Suicidality (n=16,18) | 0 | 0 |
| Week 2: Suicidal behaviour (n=16,18) | 0 | 0 |
| Week 2: Suicidal ideation (n=16,18) | 0 | 0 |
| Week 8: Suicidality (n=16,18) | 0 | 0 |
| Week 8: Suicidal behaviour (n=16,18) | 0 | 0 |
| Week 8: Suicidal ideation (n=16,18) | 0 | 0 |
| Week 18: Suicidality (n=16,14) | 0 | 0 |
| Week 18: Suicidal behaviour (n=16,14) | 0 | 0 |
| Week 18: Suicidal ideation (n=16,14) | 0 | 0 |
| Last visit: Suicidality (n=17,18) | 0 | 0 |
| Last visit: Suicidal behaviour (n=17,18) | 0 | 0 |
| Last visit: Suicidal ideation (n=17,18) | 0 | 0 |
Collected over Events were recorded starting at the time the ICF is signed up to 125 days after the study drug administration.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aripiprazole IM Depot 400 mg: Deltoid | — | 0/17 (0%) | 14/17 (82.4%) |
| Aripiprazole IM Depot 400 mg: Gluteal | — | 0/18 (0%) | 18/18 (100%) |
| Event | Aripiprazole IM Depot 400 mg: Deltoid | Aripiprazole IM Depot 400 mg: Gluteal |
|---|---|---|
| Injection site painGeneral disorders | 6/17 | 5/18 |
| HeadacheNervous system disorders | 4/17 | 4/18 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 3/17 | 2/18 |
| AkathisiaNervous system disorders | 3/17 | 3/18 |
| SomnolenceNervous system disorders | 3/17 | 0/18 |
| DizzinessNervous system disorders | 0/17 | 3/18 |
| DiarrhoeaGastrointestinal disorders | 2/17 | 1/18 |
| ToothacheGastrointestinal disorders | 2/17 | 1/18 |
| Blood creatine phosphokinase increasedInvestigations | 2/17 | 0/18 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/17 | 1/18 |
| Age, Continuous(Years) | Aripiprazole IM Depot 400 mg: Deltoid | Aripiprazole IM Depot 400 mg: Gluteal | Total |
|---|---|---|---|
| Mean | 43.1 ± 11.0 | 45.9 ± 7.3 | 44.5 ± 9.3 |
| Sex: Female, Male(Participants) | Aripiprazole IM Depot 400 mg: Deltoid | Aripiprazole IM Depot 400 mg: Gluteal | Total |
|---|---|---|---|
| Female | 6 | 4 | 10 |
| Male | 12 | 15 | 27 |
The record gives a start of May 2012, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →